Nerve Fibers in Breast Cancer Tissues Indicate Aggressive Tumor Progression

Di Huang, MD, Shicheng Su, MD, PhD, Xiuying Cui, MD, Ximing Shen, MD, Yunjie Zeng, MD, Wei Wu, MD, PhD, Jianing Chen, MD, Fei Chen, MD, Chonghua He, PhD, Jiang Liu, MD, Wei Huang, PhD, Qiang Liu, MD, PhD, Fengxi Su, MD, PhD, Erwei Song, MD, PhD, and Nengtai Ouyang, MD, PhD

Abstract: Emerging evidence has indicated nerve fibers as a marker in the progression of various types of cancers, such as pancreatic cancer and prostate cancer. However, whether nerve fibers are associated with breast cancer progression remains unclear. In this study, we evaluated the presence of nerve fibers in 352 breast cancer specimens and 83 benign breast tissue specimens including 43 cases of cystic fibrosis and 40 cases of fibroadenoma from 2 independent breast tumor center using immunohistochemical staining for specific peripheral nerve fiber markers.

In all, nerve fibers were present in 130 out of 352 breast cancer tissue specimens, while none were detected in normal breast tissue specimens. Among 352 cases, we defined 239 cases from Sun Yat-Sen Memorial Hospital, Guangzhou, China, as the training set, and 113 cases from the First Affiliated Hospital of Shantou University, Guangdong, China, as the validation set. The thickness of tumor-involving nerve fibers is significantly correlated with poor differentiation, lymph node metastasis, high clinical staging, and triple negative subtype in breast cancer. More importantly, Cox multifactor analysis indicates that the thickness of tumor-involving nerve fibers is a previously unappreciated independent prognostic factors associated with shorter disease-free survival of breast cancer patients. Our findings are further validated by online Oncomine database.

In conclusion, our results show that nerve fiber involvement in breast cancer is associated with progression of the malignancy and warrant further studies in the future.

(Medicine 93(27):c172)

INTRODUCTION

The tumor microenvironment comprises a variety of non-malignant stromal cells that play a pivotal role in tumor progression and metastasis. Among these components, nerve fibers are emerging with great pathological value in many malignancies, including those of the pancreas, colon and rectum, prostate, head and neck, and biliary tract and stomach, although their role in tumor growth and progression remains unclear. Evidence from recent studies in pancreatic and prostate cancers has shown that nerve-derived molecules such as neurotransmitters and cytokines can enhance the malignant phenotype of cancer cells, including proliferation, cell survival, and invasiveness. On the contrary, cancer cells secrete neuro-modulatory agents to induce neuroplasticity, neural invasion, and even neuropathic pain sensation. Therefore, a reciprocally interacting loop between nerves and cancer cells can be formed to promote cancer development. In organs abundantly innervated by nerve fibers, the tumor–nerve interaction seems to be an independent factor in the progression of pancreatic cancer and prostate cancer. However, whether nerve fibers also play an important role in breast cancer remains unclear. In this study, we performed a detail immunohistological evaluation of the nerve fibers in specimens from 352 patients with breast cancer from different institutions. Our data showed that the thickness of nerve fibers was an important prognostic factor in breast cancer patients. Hence, nerve–cancer interaction may play an important role in breast cancer development, and blocking the interaction may lead to novel therapeutic approaches for breast cancer.

MATERIALS AND METHODS

Patients and Tissue Specimens

We used 352 formalin-fixed paraffin-embedded tissue samples from patients with primary ductal carcinomas of the breast in this study. For the training testing set, data were obtained from 239 female patients (median age 48.7 years, range 29–84) at Sun Yat-Sen Memorial Hospital from January 2003 to March 2010. Patients with breast cancer, and with clinicopathological characteristics and follow-up information available, were included. We included another 113 patients, with the same criteria as above, from the First Affiliated Hospital of Sun Yat-Sen Memorial Hospital, Guangzhou, China.
Hospital of Shantou University, Guangdong, China, between January 1, 2008, and May 30, 2012, in the independent validation set. Additionally, benign breast tissue samples were collected from 43 patients with cystic fibrosis of the breast and benign 40 patients with breast fibroadenoma. All of the samples were collected with informed consent according to the Internal Review and the Ethics Board of the Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

**Immunohistochemistry**

Paraffin-embedded samples were sectioned into 4-μm-thick slices. Antigen retrieval was performed using a pressure cooker for 30 minutes in 0.01 M citrate buffer (pH 6.0), followed by treatment with 3% hydrogen peroxide for 5 minutes. The specimens were incubated with antibodies specific for protein gene product 9.5 (PGP9.5), neurofilament (NF), and class III-β-tubulin overnight at 4°C. Immunostaining was performed using Diaminobenzidine according to the manufacturer’s instructions. As a negative control, isotype-matched antibodies were applied.

**Specimens Analyzed**

All specimens were serially sectioned transversely, and whole-mount histologic sections were examined by 2 of the authors. The presence of nerve fibers in breast cancer specimens was defined as carcinoma within the perineural space adjacent to a nerve. To quantify the presence of nerve fibers, the maximum diameter of the nerve fibers was measured with an ocular micrometer by using Nikon NIS-Elements BR software (Nikon, Melville, NY). We selected the optimum cutoff score for the diameter of nerve fibers in breast cancer using X-tile plots based on the association with the patients’ disease-free survival (DFS). X-tile plots provide a single and intuitive method to assess the association between variables and survival. The X-tile program can automatically select the optimum data cut point according to the highest χ² value (minimum P value) defined by Kaplan–Meier survival analysis and log-rank test. We did the X-tile plots using the X-tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT).

**Data Mining**

The associations between PGP9.5 mRNA expression in tissue and the clinical features and outcomes of breast cancer were obtained using Oncomine Cancer Microarray database analysis (http://www.oncomine.org). Data were retrieved from the Oncomine web site. None of the studies at Oncomine showed contradictory results with statistical significance. Additional details of the study are available at Oncomine.

**Statistics**

All statistical analyses were performed using Statistical Package for Social Sciences software for Windows Version 13.0 (SPSS, Chicago, IL). The χ² test was applied to compare categorical data. Kaplan–Meier survival curves were plotted, and the log-rank test was applied. Groups of discrete variables were compared using the Mann–Whitney U test and the Kruskal–Wallis nonparametric analysis of variance. DFS was calculated as the time from the date of surgery to the date of the first recurrence or metastasis after surgery (in patients with recurrence or metastasis) or to the date of the last follow-up (in patients without recurrence and metastasis). Overall survival (OS) was calculated as the time from the date of diagnosis to the date of death or the date of the last follow-up (if death did not occur). The prognostic significance of clinical and pathologic characteristics was determined using univariate Cox regression analysis. Cox proportional hazards models were fitted for multivariate analysis. After the interactions between the variables were examined, a backward stepwise procedure was used to derive the best-fitting model. Both 1-sided and 2-sided tests were used for all statistical analyses and significance level was 0.05. We investigated the prognostic or predictive accuracy of the presence of nerve fibers using receiver operating characteristic (ROC) analysis. We used the area under the curve (AUC) at different follow-up times to measure prognostic or predictive accuracy.

**RESULTS**

**Nerve Fibers Are Present in Breast Cancer**

Most of previous studies examining the nerve fibers involvement in different types of cancer only used hematoxylin–eosin (H&E) staining. Although H&E staining can reveal the detailed structure of cancer specimens, immunohistochemical (IHC) staining with specific markers is more sensitive and specific than H&E staining to identify nerve fibers. To access the presence of nerve fibers in breast cancer, we examined 352 breast cancer specimens for the expression of specific neuronal markers, including PGP9.5, NF, and class III-β-tubulin, in serial sections. We found that these 3 markers demonstrated similar positive staining patterns in serial breast cancer sections, whereas the control isotype-matched antibodies demonstrated negative staining (Figure 1). Furthermore, nerve fibers identified by immunohistochemistry were validated by H&E staining in the serial sections showing a clearer histological structure of nerve fibers distributing in the tumor stroma (Figure 1). Therefore, nerve fibers are present in the stroma of breast cancer tissues.

**FIGURE 1.** Nerve fibers present in breast cancer. (A) PGP9.5. (B) NF. (C) Class III-β-tubulin. (D) Isotype-matched antibody, mouse IgG. (E) H&E staining. Represented images of nerve fibers in breast cancer specimens. Nerve fibers were detected in serial sections of breast cancer tissues using IHC staining with 3 different specific neuronal markers. Original magnifications: 100× for the wild view; 400× for the left up corner. Scale bar, 100 μm. H&E = hematoxylin–eosin, IgG = immunoglobulin G, IHC = immunohistochemical, NF = neurofilament, PGP9.5 = protein gene product 9.5.
Nerve Fibers in Breast Cancer Tissues Correlate With High Malignancy

We next correlate the presence of nerve fibers, indicated by immunohistochemistry for 3 specific neuronal markers, with breast cancer progression in the patients. Among the 352 patients examined, nerve fibers were identified in 130 (36.93%) cases and were observed at the invasive front or in the center of the tumors, whereas no staining was observed in the adjacent nonneoplastic epithelia (Figure 2A and B). Additionally, nerve fibers were absent in all benign breast tissues, including fibrocystic lesions with or without atypical epithelial hyperplasia and benign breast fibroadenoma, whereas these fibers were occasionally identified in the stroma (2 out of 18 cases) of ductal carcinomas in situ (DCIS) of the breast (noncancerous tissue vs invasive breast cancer: \( P < 0.001 \) by both 1-sided and 2-sided tests; breast DCIS vs invasive breast cancer: \( P = 0.018 \) by 1-sided test and \( P = 0.026 \) by 2-sided test; Figure 2A and B). Furthermore, among the 130 cases with the presence of nerve fibers, the immunostaining for nerve fiber markers significantly differed among various histopathological gradings. The percentage of histopathological Grade III breast cancers with PGP9.5-positive immunostaining (52.54%) was higher than those of lower histopathological gradings (the positive rate of Grade II was 36.25% [58/160, \( P = 0.007 \) by 2-sided test, \( P = 0.005 \) by 1-sided test]; the positive rate of Grade I was 13.51% [10/74, \( P < 0.001 \) by both 1-sided and 2-sided tests, compared to Grade III and Grade II; Figure 2B). Moreover, we further quantified the maximum diameter of nerve fibers in breast cancer tissues using Nikon NIS-Elements BR software. The mean diameter of the nerve fibers in invasive ductal breast cancer tissues varied from 5.84 mm to 0.00 mm.

FIGURE 2. Nerve fibers in breast cancer correlate with high malignancy. Represented images of nerve fibers in different progression of breast tissue. (A) Nerve fibers were absent in cystic fibrosis of the breast and breast fibroadenoma, while they were present in breast carcinoma in situ and invasive ductal breast cancer. The arrow indicates the involvement of nerve fibers in breast tissue specimens. Scale bar, 100 μm. (B) The graph shows that the percentage of nerve fibers involvement in different progression of breast cancer tissues varied from 11.11% to 52.54%. Red bar represents the positive rate of the nerve fibers while blue bar represents the rate of absence of nerve fibers. \( P \) values were obtained using \( \chi^2 \) test. (**: grade II vs grade III: \( P < 0.01 \) by both 1-sided and 2-sided test; ***: grade I vs grade II/III: \( P < 0.001 \) by both 1-sided and 2-sided tests.) (C) The maximum diameter of the nerve fibers in invasive ductal breast cancer samples also varied among cancer in situ and grades I–III cancers. (Mean + Standard error of mean; **: \( P < 0.01 \) by both 1-sided and 2-sided tests; ***: \( P < 0.001 \) by both 1-sided and 2-sided tests.)
fibers in Grade III breast cancer tissues was 331.2 μm, which was approximately 1.7 times greater than the mean diameter of the nerve fibers in Grade I tissues (176.8 μm, \( P < 0.001 \) by both 1-sided and 2-sided tests) and about 1.5 times greater than the one in Grade II tissues (212.6 μm, \( P < 0.01 \) by both 1-sided and 2-sided tests). However, there was no significant difference between Grade I and II breast cancers (\( P > 0.05 \) by both 1-sided and 2-sided tests; Figure 2C). Additionally, in the entire cohort, we found that the proportion of PGP9.5-positive cases was higher among high-graded primary tumors (\( P < 0.001 \) by both 1-sided and 2-sided tests), more lymph nodes metastasis (\( P = 0.007 \) by 2-sided test, \( P = 0.006 \) by 1-sided test,) and advanced clinical staging (\( P = 0.012 \) by 2-sided test, \( P = 0.009 \) by 1-sided test). However, there was no significant correlation between the presence of nerve fibers and the patients’ age, tumor size, and molecular subtyping (\( P > 0.05 \) by both 1-sided and 2-sided test) (see Table, Supplemental Digital Content 1, http://links.lww.com/MD/A78, which shows X-tile plots calculation). The figure shows the univariate analysis between diameter of nerve fibers and DFS (\( P < 0.001 \) by 2-sided test). Using X-tile plots, we included those patients with nerve fibers of diameter 0.21 mm or higher in the group at high risk of disease recurrence, and those with diameter <0.21 mm in the group at low risk of disease recurrence. The distribution of clinicopathological characteristics also varied between thinner (\( d < 0.21 \) mm) and thicker (\( d > 0.21 \) mm) group. In the training set, thicker group was associated with higher histological grade (Grade III), greater tumor burden (T3–T4), more lymph nodes metastasis (N2–N3), higher clinical tumor node metastasis stage (Stages III–IV), and poorer prognosis (Table 1, left panel). In addition, we found that nearly half of the patients (42.9%) in the thicker group have triple negative breast cancer.

To confirm that the diameter of the nerve fibers had similar prognostic value in different populations, we applied it to the independent validation set of 113 patients from different centers, classifying 93 (82.3%) patients as thinner group and 20 (17.7%) as thicker group. In the independent validation cohort, we obtained the similar results to the training set (Table 1, right panel).

To further validate these findings, we searched the Oncomine database for the expression of PGP9.5 in human breast

### TABLE 1. Correlation of the Thickness of Nerve Fibers With Clinicopathological Status in Training Cohort (239 Cases) and Validation Cohort (113 Cases) of Patients With Breast Cancer

| Training Set |  |  |  |  |
|--------------|---------------|---------------|---------------|---------------|
| No. of Patients | Nerve Fiber |  |  |  |  |
| Age, y | 239 | 206 | 33 |  |  |
| >45 | 130 | 113 (86.9%) | 17 (13.1%) | 0.851 |  |
| ≤45 | 109 | 93 (85.3%) | 16 (14.7%) |  |  |
| Histological grade |  |  |  |  |
| I | 62 | 61 (98.4%) | 1 (1.6%) | <0.001* |  |
| II | 90 | 84 (93.3%) | 7 (7.8%) |  |  |
| III | 87 | 61 (70.1%) | 25 (28.8%) |  |  |
| Tumor size, cm |  |  |  |  |
| T1–T2 | 198 | 176 (88.9%) | 22 (11.1%) | 0.013* |  |
| T3–T4 | 41 | 30 (73.2%) | 11 (26.9%) |  |  |
| Lymph node metastasis |  |  |  |  |
| N0 | 80 | 74 (92.6%) | 6 (7.5%) | 0.023* |  |
| N1 | 71 | 63 (88.7%) | 8 (11.3%) |  |  |
| N2–N3 | 88 | 69 (78.4%) | 19 (21.6%) |  |  |
| Distant organ metastasis/recurrence |  |  |  |  |
| Negative | 176 | 166 (94.3%) | 10 (5.7%) | <0.001* |  |
| Positive | 63 | 40 (63.5%) | 23 (36.5%) | 9 | 5 (55.6%) | 4 (44.4%) | 0.028* |
| Stage |  |  |  |  |
| 0–II | 143 | 134 (93.7%) | 9 (6.7%) | <0.001* |  |
| III–IV | 96 | 72 (75%) | 24 (25%) | 84 | 72 (87.8%) | 10 (12.2%) | 0.013* |
| Molecular subtyping |  |  |  |  |
| Luminal A | 71 | 59 (83.1%) | 12 (16.9%) | 0.019* |  |
| Luminal B | 135 | 122 (90.4%) | 13 (9.6%) | 62 | 56 (90.3%) | 6 (9.7%) | 0.046* |
| HER2+ | 19 | 17 (89.4%) | 2 (10.5%) | 24 | 17 (70.8%) | 7 (29.2%) |  |
| Triple negative | 14 | 8 (57.1%) | 6 (42.9%) | 7 | 4 (57.1%) | 3 (42.9%) |  |

ER = estrogen receptor, HER2+ = human epidermal growth factor receptor 2+, PR = progesteron receptor. Luminal A = ER+ and/or PR+, HER2−. Luminal B = ER+ and/or PR+, HER2+; HER2+ = ER− and PR−, HER2+. Triple negative = ER−, PR−, HER2−.

* \( P < 0.05 \), statistically difference.
### TABLE 2. Clinical Features in Breast Cancer in Oncomine Online Database

| Upregulation of PGP 9.5 in Breast Cancer | Fold Change | P Value | Database (Case Number) |
|----------------------------------------|-------------|---------|------------------------|
| Invasive ductal breast carcinoma stroma vs normal | 2.427 | 0.00016* | Ma breast 4 (66) |
| Ductal breast carcinoma in situ stroma vs normal | 1.971 | 0.00049* | |
| Invasive ductal breast carcinoma stroma vs normal | 1.844 | 0.003* | Karnoub breast (22) |
| Invasive ductal breast carcinoma vs normal | 1.528 | 0.025* | Turashvili breast (30) |
| Invasive lobular breast carcinoma vs normal | 1.299 | 0.176 | |
| Ductal breast carcinoma vs normal | 2.767 | 0.0005* | Richardson breast 2 (47) |
| Medullary breast carcinoma vs normal | 1.805 | 0.00032* | Curtis breast (2136) |
| Benign breast neoplasm vs normal | 2.073 | 0.153 | |
| Breast phyllodes tumor vs normal | 1.309 | 0.230 | |
| Ductal breast carcinoma in situ vs normal | 1.173 | 0.245 | |
| Invasive breast carcinoma stroma vs normal | 1.989 | <0.0001 | Finak breast (59) |

| Upregulation of PGP9.5 in Triple Negative Breast Cancer | Fold Change | P Value | Database |
|---------------------------------------------------------|-------------|---------|----------|
| Triple negative ductal breast carcinoma vs others | 7.736 | <0.0001* | Richardson breast (47) |
| Triple negative ductal breast carcinoma vs others | 3.127 | <0.0001* | Bittner breast (336) |
| Triple negative invasive ductal breast carcinoma vs others | 2.005 | <0.0001* | Gluck breast (158) |
| Triple negative invasive ductal breast carcinoma vs others | 2.165 | <0.0001* | Curtis breast (2136) |
| Triple negative ductal breast carcinoma vs others | 1.925 | <0.0001* | Bonnefoi breast (160) |
| Triple negative invasive breast carcinoma vs others | 1.712 | <0.0001* | Hatzis breast (508) |
| Triple negative invasive ductal breast carcinoma vs others | 5.331 | 0.00098* | Stickeler breast (57) |
| Triple negative invasive ductal breast carcinoma vs others | 1.489 | 0.00015* | Tabchy breast (178) |
| Triple negative invasive breast carcinoma vs others | 2.981 | 0.026* | Esserman breast (130) |

| Correlation of PGP9.5 and High-Graded Breast Carcinoma | Fold Change | P Value | Database |
|--------------------------------------------------------|-------------|---------|----------|
| Invasive breast carcinoma—high grade | 2.19 | <0.0001* | Hatzis breast (508) |
| Invasive breast carcinoma—high grade | 2.01 | 0.0004* | Desmedt breast (198) |
| Breast carcinoma—high grade | 1.833 | 0.275 | |
| Ductal breast carcinoma—high grade | 1.328 | 0.024* | Perou breast (65) |
| Invasive ductal breast carcinoma epithelial—high grade | 2.268 | 0.223 | Ma breast 4 (66) |

| PGP9.5 and Poor Prognosis of Breast Cancer | Fold Change | P Value | Database |
|-------------------------------------------|-------------|---------|----------|
| Metastatic event at 1 year vs others | 1.3 | 0.017* | Hatzis breast (508) |
| Metastatic event at 3 years vs others | 1.266 | 0.003* | |
| Metastatic event at 5 years vs others | 1.14 | 0.159 | |
| Metastatic event at 1 year vs others | 1.817 | 0.000724* | Bos breast (204) |
| Metastatic event at 3 years vs others | 1.431 | 0.011* | |
| Metastatic event at 5 years vs others | 1.523 | 0.037* | |
| Metastatic event at 1 year vs others | 1.457 | 0.326 | |
| Metastatic event at 3 years vs others | 1.537 | 0.058 | |
| Metastatic event at 5 years vs others | 1.795 | 0.017* | |
| Metastatic event at 1 year vs others | 2.577 | 0.050 | |
| Metastatic event at 3 years vs others | 1.609 | 0.036* | |
| Metastatic event at 5 years vs others | 1.263 | 0.111 | |
| Metastatic event at 1 year vs others | 1.300 | 0.017* | Kao breast (327) |
| Metastatic event at 3 years vs others | 1.467 | 0.000598* | |
| Metastatic event at 5 years vs others | 1.186 | 0.1 | |
| Metastatic event at 1 year vs others | 1.040 | 0.017* | Symmans breast (195) |
| Metastatic event at 3 years vs others | 1.375 | 0.014* | |
| Metastatic event at 5 years vs others | 1.348 | 0.026* | |
| Metastatic event at 1 year vs others | 1.082 | 0.007* | |
| Metastatic event at 3 years vs others | 1.047 | 0.035* | |
| Metastatic event at 5 years vs others | 1.117 | 0.016* | |
| Recurrence event at 3 years vs others | 1.375 | 0.014* | |
| Recurrence event at 5 years vs others | 1.815 | 0.043* | |
| Recurrence 3 years vs others | 1.069 | 0.009* | |
| Dead event at 3 years vs others | 1.195 | 0.049* | |

© 2014 Lippincott Williams & Wilkins
cancer. Four datasets showed that the expression of PGP9.5 in breast cancer was higher compared to normal breast tissue, while 3 datasets showed an association between PGP9.5 expression and high-grade breast cancer with approximately 2-fold increase (Table 2). Furthermore, approximately 9 datasets showed that the expression of PGP9.5 was associated with metastasis, recurrence, or patient death during follow-up. The results found in the Oncomine database confirmed our findings that the involvement of nerve fibers is associated with breast cancer progression.

### Thickness of Nerve Fibers Predict Prognosis for Breast Cancer Patients

Tumor recurrence and distant metastasis are responsible for poor survival of breast cancer patients. Therefore, we

### TABLE 2. (Continued)

| PGP9.5 and Poor Prognosis of Breast Cancer | Fold Change | P Value | Database |
|-------------------------------------------|-------------|---------|----------|
| Dead event at 3 years vs others           | 1.114       | 0.010⁷  | Vandevijver breast (295) |
| Dead event at 5 years vs others           | 1.086       | 0.005⁷  | Loi breast (87) |

PGP9.5 = protein gene product 9.5.

*P < 0.05, statistically difference.

### Correlation of PGP9.5 and Advanced N Stage of Breast Cancer

| N1 vs N0 | Fold Change | P Value | Database |
|----------|-------------|---------|----------|
| N1 vs N0 | 1.837       | 0.007⁷  | Ma breast 4 (66) |
| N1 vs N0 | 1.325       | 0.007⁷  | Loi breast (87) |

---

**FIGURE 3.** Diameter of nerve fibers can be a prognostic marker of breast cancer. The diameter of nerve fibers of every breast cancer patients in (A) training set (left) and validation set (right). (B) The cutoff value (d = 0.21 mm) was automatically generated by X-tile plots. Time-dependent ROC curves in the training set (left) and validation set (right). Data are AUC (95% CI) or hazard ratio (95% CI). Upper panel showed data of 1 year follow-up, whereas down panel showed data of 5 years follow-up. (C) Kaplan–Meier survival curve of DFS and OS in training set (left) and validation set (right). AUC = area under the curve, CI = confidence interval, DFS = disease-free survival, OS = overall survival, ROC = receiver operator characteristic.
analyzed the prognostic value of PGP9.5 expression in the training cohort and the independent validation cohort using Kaplan–Meier analysis and log-rank test. In the training cohort, 40 out of 206 cases with thinner nerve fibers (d < 0.21 mm) developed local recurrence (15 cases) and/or distant recurrence (25 cases), whereas 23 of 33 cases with thicker nerve fibers (d > 0.21 mm) developed local recurrence (5 cases) and/or distant recurrence (18 cases) (Figure 3A, left panel). The median follow-up period for all patients was 84 months, ranging from 12 to 117 months. The breast cancer patients with thinner nerve fibers had a median DFS of 82 months, which was significantly longer than the 74-month DFS for patients with nerve fibers (P < 0.001 by both 1-sided and 2-sided tests). Breast cancer patients with thicker nerve fibers also demonstrated shorter OS (median: 82 months) compared to those with thinner nerve fibers (median 90 months; P < 0.001 by both 1-sided and 2-sided tests; Figure 3C, left panel).

We assessed the sensitivity and specificity of prognostic value of the diameter of nerve fibers with time-dependent ROC analysis at varying follow-up times (Figure 3B, left panel). The ROC curve analysis showed that diameter of the nerve fibers performed better in 1 year follow-up group (AUC = 0.884; 95% confidence interval [CI]: 0.777–0.990) than 5 years follow-up groups (AUC = 0.755; 95% CI: 0.657–0.852, Figure 3B).

Similarly, these results were confirmed in validation cohort, as shown in Figure 3 A–C, right panel.

The results of univariate Cox regression analysis for DFS are shown in Table 3. In training cohort, DFS was significantly associated with tumor size, positive lymph node status, pathological stage, histopathological grading, and the diameter of nerve fibers and human epidermal growth factor receptor 2 (HER2) status (P < 0.05 by 2-sided test). There was no significant association of DFS with age, estrogen receptor status, and progesterone receptor status (P > 0.05 by 2-sided test). In the multivariate analysis (Table 4), lymph node status, histological grade, the diameter of nerve fibers, and HER2 status were independent prognostic factors for DFS (P < 0.05 by 2-sided test). We also noted similar results in the independent validation set. Collectively, our data suggest that the thickness of the nerve fibers might serve as a previously unappreciated prognostic predictor of the long-term survival of breast cancer patients.

### Nerve Fibers at the Invasive Front, But Not the Center of Breast Cancer Tissues Predict Poor Patient Outcome

We observed nerve fibers in 2 different locations within breast cancer specimens. In the entire cohort, nerve fibers were

| TABLE 3. Univariate Cox Regression Analysis of Disease-Free Survival in Relation to Clinicopathologic Features |
| Training Set (n = 239) | Validation Set (n = 113) |
|------------------------|--------------------------|
| **Age, y** | **HR (95% CI)** | **P Value** | **HR (95% CI)** | **P Value** |
| >45 | 1 | 0.969 | 1 | 0.320 |
| <45 | 0.989 (0.576–1.699) | 0.468 (0.105–2.091) | 0.011 |
| **Histological grade** | | | | |
| I | 1 | 0.007* | 1 | 0.027* |
| II–III | 2.739 (1.315–5.706) | 2.233 (1.220–4.088) | 0.046 |
| **Tumor size, cm** | | | | |
| T1–T2 | 1 | 0.037* | 1 | 0.025* |
| T3–T4 | 1.512 (0.874–3.616) | 2.856 (0.541–15.081) | 0.011 |
| **Lymph node metastasis** | | | | |
| Negative | 1 | <0.001* | 1 | <0.001* |
| Positive | 3.307 (1.613–6.780) | 4.293 (1.864–20.333) | 0.025 |
| **Stage** | | | | |
| 0–II | 1 | <0.001* | 1 | <0.001* |
| III–IV | 2.948 (1.699–5.116) | 16.814 (2.053–37.714) | 0.027 |
| **Diameter of nerve fiber, mm** | | | | |
| ≤0.21 | 1 | <0.001* | 1 | 0.256 |
| >0.21 | 5.229 (2.887–9.470) | 5.298 (1.209–23.212) | 0.307 |
| **ER status** | | | | |
| Negative | 1.705 (0.878–3.312) | 0.447 (0.111–1.792) | 0.474 (0.113–1.986) |
| Positive | 1 | 0.454 | 1 | 0.506 |
| **PR status** | | | | |
| Negative | 1.332 (0.627–2.831) | 0.474 (0.113–1.986) | 0.536 |
| Positive | 1 | 0.033* | 1 | 0.056 |
| **HER2 status** | | | | |
| Negative | 2.581 (1.865–3.889) | 2.161 (0.628–6.145) | 0.036 |

CI = confidence interval, ER = estrogen receptor, HER2 = human epidermal growth factor receptor, HR = hazard ratio, PR = progesterone receptor.

*P < 0.05, statistically difference.
Table 4. Multivariate Cox Regression Analysis of Disease-Free Survival in Relation to Clinicopathologic Features

|                          | Training Set (n = 239) | Validation Set (n = 113) |
|--------------------------|------------------------|--------------------------|
|                          | HR (95% CI)            | P Value                  | HR (95% CI)            | P Value                  |
| Histological grade       |                        |                          |                         |                          |
| I                        | 1                      | 0.025*                   | 1                       | 0.021*                   |
| II–III                   | 1.605 (1.061–2.430)    | 0.025*                   | 2.981 (1.657–5.364)    | 0.021*                   |
| Tumor size, cm           |                        |                          |                         |                          |
| T1–T2                    | 1                      | 0.427                    | 1                       | 0.199                    |
| T3–T4                    | 1.260 (0.712–2.229)    | 0.031*                   | 4.097 (1.476–21.249)   | 0.054                    |
| Lymph node metastasis    |                        |                          |                         |                          |
| Negative                 | 2.342 (1.754–3.389)    | 0.031*                   | 1.729 (0.429–10.161)   | 0.054                    |
| Positive                 | 1                      | 0.510                    | 7.109 (2.636–29.503)   | 0.111                    |
| Stage                    |                        |                          |                         |                          |
| 0–II                     | 1                      | <0.001*                  | 1                       | 0.038*                   |
| III–IV                   | 1.381 (0.528–3.613)    | 0.001*                   | 6.016 (2.941–10.478)   | 0.038*                   |
| Diameter of nerve fiber, mm |                        |                          |                         |                          |
| ≤0.21                    | 1                      | <0.001*                  | 1                       | 0.179                    |
| >0.21                    | 4.543 (2.349–8.784)    | 0.001*                   | 2.279 (1.204–4.316)    | 0.179                    |
| HER2 status              |                        |                          |                         |                          |
| Negative                 | 1                      | 0.179                    | 1                       | 0.179                    |
| Positive                 | 2.279 (1.204–4.316)    | 0.001*                   | 1.971 (0.273–11.145)   | 0.179                    |

CI = confidence interval, ER = estrogen receptor, HER2 = human epidermal growth factor receptor, HR = hazard ratio, PR = progesterone receptor.
*P < 0.05, statistically difference.

Neuron-specific cytoskeletal components that allow nerve cells to establish and grow.21 Class III-β-tubulin is abundant in neuronal tissue,22 Kulchitsky neuroendocrine cells, and neuronal tumors,23 and associated with neuronal differentiation.24 But it was also reported in other cell types, such as breast cancer cells.25 Therefore, we identified nerve fibers by all 3 markers (PGP9.5, NF, and class III-β-tubulin) stained positively. By using IHC and H&E staining, we found that nerve fibers were present in 130/352 cases (36.93%) of breast cancer. The higher rates of nerve fiber involvement in our studies compared to the previous studies suggest that IHC and H&E staining is more appropriate approach to detect nerve fiber involvement.

The neurotrophic factors secreted from cancer cells and other stromal cells promote the hypertrophy of nerve fiber in cancer, which reciprocally drive the cancer progression by producing various biological mediators. Therefore, we further evaluated the nerve fibers in breast cancer tissue by classifying it as thinner group (d ≤ 0.21 mm) and thicker group (d > 0.21 mm). The diameter of nerve fibers correlated with positive lymph node metastasis, high histological grade, and advanced clinical stage. More importantly, the thickness of nerve fibers in breast cancer is associated with worse DFS and OS independent of other conventional prognostic factors. Moreover, our findings were further validated by 19 online databases with information of breast cancer patients.

Previous studies13 have reported that tumor-infiltrating sympathetic fibers arising from normal prostate tissue play an important role in initial tumor growth, while intratumoral parasympathetic fibers can promote the proliferation and invasion of cancer cells. In our study, we also found that nerve fibers in breast cancer specimens were located at 2 distinct sites; they were often observed at the invasive front (89/130) and less frequently observed at the center of the cancerous tissue.
The positive rate of nerve fibers at the invasive front was associated with high histological grade, positive lymph node metastasis, and poor prognosis, while the positive rate of nerve fibers at the center of the cancer was only correlated with advanced histological grade. The difference between these 2 types of nerve fibers suggests that they may have distinctive functions during cancer progression and warrant further studies in the future.

Randomized clinical studies have demonstrated that psychological distress in breast cancer patients can make tumors resistant to chemotherapy, and this process represents a significant reason for poor prognosis.\(^{26,27}\) Furthermore, these findings have been confirmed in cell culture studies and animal experiments.\(^{28}\) Although the mechanisms by which psychological distress affects the progression of breast cancers remain poorly understood, ample evidence has suggested that psychological stress can alter hormonal and neuronal secretions.\(^{29}\) These alterations can result in high levels of tissue catecholamine and adrenaline, which have a strong impact on the biological activities of breast cancer cells.\(^{30}\) In addition, chronic elevated levels of adrenaline and noradrenaline, which may increase tumor’s invasiveness, have been reported in the plasma and urine of breast cancer patients.\(^{31}\) Moreover, recent retrospective clinical data suggest that patients with many malignant cancers, including prostate cancer,\(^{32}\) melanoma,\(^{33}\) and breast cancer,\(^{34,35}\) who take β-blockers, have a better prognosis and lower recurrence and mortality rates. In this study, we investigated this phenomenon in breast cancer patients and found that nerve fibers also exist in the breast cancer tissues and are associated with a poor prognosis in breast cancer patients. Therefore, our and other studies suggest that the nerve–tumor interaction may play an essential role in breast cancer progression and represent a potential therapeutic target for breast cancer.

ACKNOWLEDGEMENTS

This work was supported by Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University, Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology, Natural Science Foundation of China(81372819), Ministry of Education of China (2012071110075) and funding from Sun Yat-Sen University (13ykzd14), Grants 973 (2010CB912800, 2011CB504203) Projects from Ministry of Science and Technology of China, the Natural Science Foundation of China (81230060, 81261140373, 81472468), Science Foundation of Guangdong Province(S2012030006287), Funding from Guangzhou Science and Technology Bureau(20134100059).

REFERENCES

1. Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19:541–555.
2. Cheong H, Lu C, Lindsten T, et al. Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012;30:671–678.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
4. Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25:605–620.
5. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319–328.
6. Liu B, Lu KY. Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat Dis Int. 2002;1:469–476.
7. Pour PM, Bell RH, Batra SK. Neural invasion in the staging of pancreatic cancer. Pancreas. 2003;26:322–325.
8. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666.
9. Ayala GE, Wheeler TM, Shine HD, et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001;49:213–223.
10. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2009;359:1143–1154.
11. Scartozi M, Galizia E, Verdeccchia L, et al. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer. 2006;95:445–449.
12. Schweizerhof M, Stosser S, Kurejova M, et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009;15:802–807.
13. Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.
14. Demir IE, Friess H, Ceyhan GO. Nerve-cancer interactions in the stromal biology of pancreatic cancer. Front Physiol. 2012;3:97.
15. Blauboer ME, Boeijen FR, Emson CL, et al. Extracellular matrix proteins: a positive feedback loop in lung fibrosis? Matrix Biol. 2014;34:170–178.
16. Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115:3379–3391.
17. Yamaguchi M, Ito A, Okamoto N, et al. Heat-inducible transgene expression system incorporating a positive feedback loop of transcriptional amplification for hyperthermia-induced gene therapy. J Biosci Bioeng. 2012;114:460–465.
18. Marchesi F, Piemonti L, Mantovani A, et al. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 2010;21:77–82.
19. Osborn DP, Li K, Hinits Y, et al. Cdkn1c drives muscle differentiation through a positive feedback loop with Myod. Dev Biol. 2011;350:464–475.
20. Wilson PO, Barber PC, Hamid QA, et al. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol. 1988;69:91–104.
21. Carden MJ, Trojanowski JQ, Schlaepfer WW, et al. Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci. 1987;7:3489–3504.
22. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton. 2003;55:77–96.
23. Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med. 2000;124:535–544.
24. Katsetos CD, Legido A, Perentes E, et al. Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol. 2013;18:851–866.
25. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9:168–175.
26. Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29:413–420.
27. Kornblith AB, Herndon JE 2nd, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98:679–689.
28. Su F, Ouyang N, Zhu P, et al. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun. 2005;329:888–897.
29. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol. 2004;22:3570–3580.
30. Drell TLt, Joseph J, Lang K, et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63–70.
31. Aragona M, Muscatello MR, Losi E, et al. Lymphocyte number and stress parameter modifications in untreated breast cancer patients with depressive mood and previous life stress. J Exp Ther Oncol. 1996;1:354–360.
32. Grytlit HH, Fagerland MW, Fossa SD, et al. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73:250–260.
33. Lemeshow S, Sorenson HT, Phillips G, et al. Beta-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2011;20:2273–2279.
34. Barron TL, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29:2635–2644.
35. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645–2652.